If you have been reading about Thiol and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Measuring glutathione in biological samples requires attention to oxidation, because GSH can convert to GSSG after sample collection. Blood and plasma samples are often treated with acid or alkylating agents to preserve the reduced form. Without stabilization, apparent GSH concentrations can fall while GSSG rises. Differences in sample type, handling delay, and deproteinization method can produce results that are not comparable across studies. Reporting preanalytical details is therefore important for interpreting findings.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. Enzymatic recycling measures total glutathione after converting GSSG back to GSH, while separation methods can quantify GSH and GSSG separately. Derivatization may be used to improve detection or stability during analysis. LC-MS/MS offers high specificity and can distinguish glutathione from related thiols and adducts. Each method has different sensitivity, throughput, and susceptibility to interference, so method selection depends on the study question and sample matrix.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
In its reduced form, glutathione carries a sulfhydryl group that can donate electrons. This property lets it act as a major cellular antioxidant and redox buffer. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid peroxides, while glutathione reductase regenerates the reduced form using NADPH. The ratio of reduced glutathione to glutathione disulfide is widely used as an indicator of oxidative stress, though the ratio changes with compartment, cell type, and sample handling. Oxidized glutathione can also form mixed disulfides with proteins, affecting their activity.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS/MS, HPLC, or enzymatic recycling | Choice depends on whether total, reduced, or oxidized glutathione is measured. |
| Sample stabilization | Acidification or thiol alkylation | Helps limit conversion of GSH to GSSG after collection. |
| Solution stability | Limited at room temperature | Oxidation and pH-dependent degradation can occur. |
| Storage of solid | -20 °C, desiccated, protected from light | Common for research reagents; follow supplier instructions. |
| Common interference | Other thiols and metal ions | Can affect separation or enzymatic detection. |
Samples for glutathione analysis require careful handling because the compound oxidizes readily and can be consumed by enzymes after collection. Blood is often treated with acid or thiol-blocking agents soon after draw, and plasma should be separated quickly from red blood cells. Tissues are usually snap-frozen or extracted immediately. Aqueous solutions of glutathione are less stable than dry powder and degrade faster at neutral or alkaline pH, in light, or with dissolved oxygen. Repeated freeze-thaw cycles also reduce reliability.
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
Because GSH is central to redox balance, its status is studied in aging, liver disease, neurodegenerative conditions, and metabolic disorders. Observational studies often report lower GSH or higher GSSG in affected tissues, but such associations do not establish that raising glutathione changes disease outcomes. Oral glutathione is digested into amino acids, and whether intact absorption occurs remains debated; precursors such as N-acetylcysteine and cysteine donors are also investigated. Regulatory agencies generally treat glutathione as a dietary supplement, not an approved drug, and clinical claims require evidence from controlled trials.
Glutathione is a small tripeptide composed of glutamate, cysteine, and glycine, with the unusual gamma-glutamyl linkage between glutamate and cysteine. Its cysteine thiol group makes it a major non-enzymatic antioxidant in cells. The reduced form, GSH, predominates in most intracellular compartments, while the oxidized disulfide form, GSSG, is produced when GSH reduces reactive oxygen species. Intracellular concentrations often reach millimolar levels, whereas plasma concentrations are much lower, typically in the low micromolar range. This gradient reflects active synthesis, transport, and consumption rather than passive distribution.
Synthesis occurs in two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine to form gamma-glutamylcysteine, and glutathione synthetase adds glycine to complete the tripeptide. The pathway is feedback-inhibited by GSH and limited by cysteine availability, so cysteine supply often constrains production. Once formed, GSH participates in redox buffering, xenobiotic conjugation, and protein glutathionylation. Glutathione peroxidase uses GSH to reduce hydrogen peroxide and lipid peroxides, yielding GSSG, while glutathione reductase regenerates GSH using NADPH. Glutathione S-transferases conjugate electrophiles to GSH, supporting detoxification and excretion.
The first sizeable batch of Boer prisoners taken by the British consisted of those captured at the Battle of Elandslaagte on 21 October 1899. Initially, these POWs were held on troopships in Simons Bay until POW camps in Cape Town and Simonstown were completed. In total, six prisoner of war camps would be set up in South Africa. As numbers grew, the British decided they did not want them kept locally. The capture of 4000 POWs in February 1900 was a key event, which made the British realise they could not accommodate all POWs in South Africa. The British feared they could be freed by sympathetic locals. Moreover, they already had trouble supplying their troops and did not want the added burden of sending supplies for the POWs. Britain therefore sent many POWs overseas. Around 31 prisoner of war camps were consequently set up in British colonies overseas during the war. The first overseas (off African mainland) camps were opened in Saint Helena, which ultimately received about 5,000 POWs. About 5,000 POWs were sent to Ceylon. Other POWs were sent to Bermuda and India.
== History == AryoGen Pharmed is the first and largest mAb producer in MENA region with the vision of manufacturing high-quality biosimilar products for patients suffering from life-threatening diseases around the world and improving patient’s quality of life. AryoGen pharmed produces its own Active Pharmaceutical Ingredients (APIs) Using large-scale bioreactors according to cGMP guidelines, which have been approved by PIC/s members. Research and Development unit with laboratory-scale and pilot-scale production lines is equipped with cell culture equipment such as bioreactors and recombinant protein purification Facility. The state-of-the-art manufacturing sites of AryoGen have received major accreditation such as EU GMP European Medicines Agency (EMA). The quality of all products have been certified by the most reputable laboratories around the world. AryoGen Pharmed has several Tech-Transfer projects in different countries such as Turkey, Russia and Tunisia. In addition, the products of AryoGen Pharmed have been exported to different countries in Asia, Africa and Latin America.
=== Global market === During the 2000s, Biocon established its subsidiary Biocon Biologics and substantially grew its production of existing drugs for the American and European markets. Regulatory bodies such as the American Food and Drug Administration and various European state agencies (later the European Commission) have approved Biocon for production of many such products, starting with lovastatin in 2001. Biocon's production largely focused on generics, which as of 2022 had saved European healthcare systems some €30 billion in drug costs. In the 2010s, Biocon began rapidly expanding its production and market reach. In 2008, Biocon acquired a 70% stake in German pharmaceutical company AxiCorp GmbH. The following year, Biocon established a partnered research facility in Bengaluru with American pharmaceutical corporation Bristol Myers Squibb, and announced a strategic collaboration with Mylan to enter the global generic biologics market. The following years saw a steady expansion of major Biocon production facilities in Asian nations, including Malaysia in 2010, and in Bangalone in 2016 with partner Amgen.
Sources: en.wikipedia.org
== Challenges == RNAi intersects with a number of other pathways; as of 2010, it was not surprising that, on occasion, nonspecific effects were triggered by the experimental introduction of an siRNA. When a mammalian cell encounters a double-stranded RNA such as an siRNA, it may mistake it as a viral by-product and mount an immune response. Furthermore, because structurally related microRNAs modulate gene expression largely via incomplete complementarity base pair interactions with a target mRNA, the introduction of an siRNA may cause unintended off-targeting. Chemical modifications of siRNA may alter the thermodynamic properties that also result in a loss of single nucleotide specificity. Because siRNA drugs are oligonucleotides rather than small molecules, they are not substrates for cytochrome P450 enzymes and do not induce or inhibit CYP-mediated metabolism at clinically relevant concentrations. Drug–drug interaction (DDI) assessment therefore focuses on endocytic transporter pathways, off-target mRNA silencing, and in cases where the silenced target gene encodes a regulator of drug metabolism secondary effects on CYP or transporter expression.
Some species of yeast are opportunistic pathogens that can cause infection in people with compromised immune systems. Cryptococcus neoformans and Cryptococcus gattii are significant pathogens of immunocompromised people. They are the species primarily responsible for cryptococcosis, a fungal infection that occurs in about one million HIV/AIDS patients, causing over 600,000 deaths annually. The cells of these yeast are surrounded by a rigid polysaccharide capsule, which helps to prevent them from being recognised and engulfed by white blood cells in the human body. Yeasts of the genus Candida, another group of opportunistic pathogens, cause oral and vaginal infections in humans, known as candidiasis. Candida is commonly found as a commensal yeast in the mucous membranes of humans and other warm-blooded animals. However, sometimes these same strains can become pathogenic. The yeast cells sprout a hyphal outgrowth, which locally penetrates the mucosal membrane, causing irritation and shedding of the tissues. A book from the 1980s listed the pathogenic yeasts of candidiasis in probable descending order of virulence for humans as: C. albicans, C. tropicalis, C. stellatoidea, C. glabrata, C. krusei, C. parapsilosis, C. guilliermondii, C. viswanathii, C. lusitaniae, and Rhodotorula mucilaginosa. Candida glabrata is the second most common Candida pathogen after C. albicans, causing infections of the urogenital tract, and of the bloodstream (candidemia). C. auris has been more recently identified.
== Health risks == Acrolein is toxic and is a strong irritant for the skin, eyes, and nasal passages. The main metabolic pathway for acrolein is the alkylation of glutathione. The WHO suggests a "tolerable oral acrolein intake" of 7.5 μg per day per kg of body weight. Although acrolein occurs in French fries (and other fried foods), the levels are only a few μg per kg, meaning that one would have to consume more than their body weight in fries every day to surpass the limit set by the WHO. In response to occupational exposures to acrolein, the US Occupational Safety and Health Administration has set a permissible exposure limit at 0.1 ppm (0.25 mg/m3) at an eight-hour time-weighted average. Acrolein acts in an immunosuppressive manner and may promote regulatory cells, thereby preventing the generation of allergies on the one hand, but also increasing the risk of cancer. Acrolein was identified as one of the chemicals involved in the 2019 Kim Kim River toxic pollution incident.
==== Nemaline myopathy ==== Nemaline myopathy was first described in 1963 and is the most common congenital myopathy. It is characterized by generalized muscle weakness and low muscle tone. In its severest form, affected babies often die from respiratory failure. To date, 9 gene mutations have been found to cause nemaline myopathy. 6 of the identified genes are associated with the actin filament, which is the basis for muscle contraction. Histologically, nemaline rods stain red with Gomori's trichrome and are mostly seen in the subsarcolemmal region of muscle fibres. Nemaline rods have also been observed in the intermyofibrillar region of muscle fibres and within the nucleus. Nemaline myopathy is an autosomal dominant and sometimes an autosomal recessive genetic disorder. Sporadic cases have also been described.
Sources: en.wikipedia.org
Preanalytical factors such as sample type, time to processing, and stabilization method can change GSH and GSSG amounts. Analytical method and calibration also contribute to variation. Comparing absolute values across studies requires caution.
These assays typically measure total glutathione after oxidizing or reducing steps convert GSSG to GSH. A colorimetric or fluorometric signal is proportional to the recycling reaction. They generally do not report GSH and GSSG separately unless additional steps are used.
Solutions are often prepared fresh and kept cold, with protection from light and oxygen exposure. Chelating agents may reduce metal-catalyzed oxidation. Storage recommendations vary by buffer, pH, and concentration, so protocol-specific guidance should be followed.
It is a tripeptide of glutamate, cysteine, and glycine. The glutamate-cysteine bond is unusual because it forms through the gamma-carboxyl group.